Corvus rewrites the Soquelitinib story: from eczema drug to immunology platform, funded by a balance-sheet reset
The AD-era keyword lexicon (EASI, IGA, JAK, Dupilumab) is fading as asthma, HS, non-T2 and 'free remissions' momentum surges — a strategic pivot financed by a $189M raise that took cash runway from 0.3 to 3.9 quarters.
CRVS · Earnings Call · 2026-08-06
The vocabulary of a pivot
The clearest sign of change at Corvus this quarter isn't a single number — it's the vocabulary. The keywords that defined the atopic-dermatitis era are sliding off the momentum leaderboard: EASI 75, IGA 0, EASI 90, JAK inhibitor, Dupilumab and inflammatory disease all registered down moves in the latest quarter. In their place, a new lexicon has colonized the top of the company keyword trajectory: non-T2, free remissions, futility analysis, and the asthma trial. Management is explicit that Soquelitinib is no longer a lymphoma-and-eczema drug — it is becoming an immunology platform. At the SID meeting, Stanford investigators presented data on persistent Treg induction that, in Miller's framing, may “usher in a new treatment paradigm for autoimmunity” — Richard A. Miller, Chief Executive Officer · 2026-08-06.Three fronts, one molecule
The PTCL registration program provides the backbone. Enrollment is "on track" toward 150 patients, with the key interim event — a DMC-run futility analysis — now expected in Q1 2027. Asked whether the interim had slipped a quarter, Miller was blunt about the event-driven reality: “We anticipate the final data late 2027, as originally stated. The interim analysis... is projected based on events.” — Richard A. Miller, Chief Executive Officer · 2026-08-06 The mechanism's breadth shows up next in atopic dermatitis, where the 200-patient, 12-week Phase II SEERA-1 study (no open-label extension, deliberately — to avoid obscuring durable remissions) reads out in Q3 2027, and in China via partner ANGEL, whose first cohort data should land before year-end 2026. On dosing, management sees a path to simplification: “a single dose of 200 milligrams will completely saturate the ITK target” — Richard A. Miller, Chief Executive Officer · 2026-08-06 — pointing toward an eventual once-daily AD regimen. But the genuinely new ground is respiratory. Corvus is launching its own Phase II asthma trial later this year alongside a Phase 1b proof-of-concept in hidradenitis suppurativa (up to 25 patients, starting September, no placebo). The design choice that sets these apart is enrolling both eosinophilic (T2) and non-eosinophilic (non-T2) asthma, with an interim allowing the company to drop either phenotype: “We are allowing both T2 and non T2. That is we will take patients above 150 and below 150 eosinophils.” — Richard A. Miller, Chief Executive Officer · 2026-08-06 That roughly doubles the addressable population versus most asthma programs, and it leans on the Th17 cell biology the HS push has highlighted.The makeover is funded
This platform expansion would have been impossible a year ago. A Q1 follow-on offering brought in $189M in net proceeds, lifting cash to $215M at June 30 versus $56.8M at year-end — management now guides that cash funds operations into Q2 2028. The balance-sheet reset is stark: liabilities-to-assets collapsed from a 42% peak to about 5%. The costs of the pivot are visible too — R&D expense roughly doubled to $16M in Q2, with net loss widening to $18M.Why it matters
The differentiation story — durability without rebound — is the load-bearing wall. Miller positioned Soquelitinib against degraders and biologics that require continuous dosing, a point he has made consistently since early 2026: “we have over 90% of our patients don't relapse and follow-up now out to 3 months beyond the last dose.” — Richard Miller, Chief Executive Officer · 2026-03-12 In this quarter he sharpened the attack, pointing to disease rebound with dupilumab, JAK inhibitors, and STAT6 degraders — an implicit jab at peers like Kymera, echoing a prior call's skepticism: “I am personally shocked that Kymera with no placebo and an interesting study for sure.” — Richard Miller, Chief Executive Officer · 2026-03-12The mechanism also tilts toward a Chinese population that, as Miller notes, skews Th17 and responds poorly to IL-4/IL-13 agents. The parallel ANGEL asthma study — identical protocols, run independently — is designed to confirm the biology in a market the company is betting on.Now we think it is very important if we have sustained remissions that do not require drug that represents, I think, an amazing opportunity and unique advantage for Soquelitinib.
The tape, meanwhile, is voting with the broader cohort. The last 90 days show a heavy small-cap biotech bid across themes like significant unmet need and Phase 1 readouts. Yet CRVS itself sits 43% below its January peak and is roughly flat over 90 days — the market is still pricing a single indication rather than the platform. If the ANGEL cohort reads out cleanly before year-end and the futility analysis clears in Q1 2027, that discount is the opportunity — and the risk.since we block the differentiation of activated Th17 and Th17 cells, we would expect to see activity in both T2 and non T2.